Feeds:
Posts
Comments

Archive for the ‘BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics’ Category

18th Annual 2019 BioIT, Conference & Expo, April 16-18, 2019, Boston, Seaport World Trade Center, Track 5 Next-Gen Sequencing Informatics – Advances in Large-Scale Computing, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 1: Next Generation Sequencing (NGS)

18th Annual 2019 BioIT, Conference & Expo, April 16-18, 2019, Boston, Seaport World Trade Center, Track 5 Next-Gen Sequencing Informatics – Advances in Large-Scale Computing

 

https://www.bio-itworldexpo.com/programs

https://www.bio-itworldexpo.com/next-gen-sequencing-informatics

 

 

 

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

represented by Founder & Director, Aviva Lev-Ari, PhD, RN will cover this event in REAL TIME using Social Media

@pharma_BI

@AVIVA1950

@evanKristel 

 

TUESDAY, APRIL 16

2:00 – 6:30 Main Conference Registration Open

 

4:00 PLENARY KEYNOTE SESSION
Amphitheater

5:00 – 7:00 Welcome Reception in the Exhibit Hall with Poster Viewing

 

WEDNESDAY, APRIL 17

7:30 am Registration Open and Morning Coffee

8:00 PLENARY KEYNOTE SESSION
Amphitheater

9:45 Coffee Break in the Exhibit Hall with Poster Viewing

 

CURRENT AND EMERGING TECHNOLOGIES
Waterfront 3

10:50 Chairperson’s Remarks

David LaBrosse, Director, Genomics, Research, Life Sciences & Healthcare, NetApp

11:00 Long Read Sequencing

Justin Zook, PhD, Researcher, National Institute of Standards and Technology

11:20 NovoGraph: Loading 7 Human Genomes into Graphs

Evan Biederstedt, Computational Biologist, Memorial Sloan Kettering Cancer Center

11:40 Building a Usable Human Pangenome: A Human Pangenomics Hackathon Run by NCBI at UCSC

Ben Busby, PhD, Scientific Lead, NCBI Hackathons Group, National Center for Biotechnology Information (NCBI)

netapp12:00 pm Co-Presentation: Faster Genomic Data

Michael Hultner, PhD, Senior Vice President, Strategy; General Manager, US Operations, PetaGene

David LaBrosse, Director, Genomics, Research, Life Sciences & Healthcare, NetApp

Genetic testing demand is driving up the volume of genomic data that must be processed, analyzed, and stored. Gigabyte-scale genome sample files and terabyte- to petabyte-scale cohort data sets must be moved from data generation to processing to analysis sites, historically a slow, arduous process. NetApp and PetaGene will describe compression and data transfer technologies that overcome I/O bottlenecks to accelerate the movement of genomic data and reduce the time to process and analyze it.

12:30 Session Break

12:40 Luncheon Presentation I: Deep Phenotypic and Genomic Analysis of UK Biobank Data on the WuXi NextCODE Platform

Saliha Yilmaz, PhD, Research Geneticist, WuXi NextCODE

The increasing size and complexity of genetic and phenotypic data to include hundreds of thousands of participants poses a significant challenge for data storage and analysis. We demonstrate use of the GOR database and query language underlying our platform to mine UK Biobank and other datasets for efficient phenotype selection, GWAS and PheWAS, and to archive and query the results.

Seven-Bridges-rectangular1:10 NEW: Luncheon Co-Presentation II: Optimizing Drug Discovery and Development with Data-Driven Insights

Christian Frech, PhD, Associate Director, Scientific Operations, Seven Bridges

Serhat Tetikol, Research & Development Engineer, Seven Bridges

1:40 Session Break

DATA VISUALIZATION, EXPLORATION & ANALYSIS
Waterfront 3

1:50 Chairperson’s Remarks

Jeffrey Rosenfeld, PhD, Manager of the Biomedical Informatics Shared Resource and Assistant Professor of Pathology, Rutgers Cancer Institute of NJ

1:55 AbbVie’s Target and Genomics Compilation (ATGC): A Target Knowledge Platform

Rishi Gupta, PhD, Senior Research Scientist, Information Research, AbbVie, Inc.

Author: Anne-Sophie Barthelet, Scientific Developer, Discngine

ATGC is a web-based platform that allows AbbVie scientists to gather relevant information to make accurate decisions on target ID, target validation, biomarker selection and drug discovery. This platform provides in-depth information on several key pieces of information such as gene expression, RNA expression, protein expression, mouse knockout studies, etc. for each target. This talk focuses on key aspects of this application including application architecture, currently available tool sets and how various pieces of information are provided to the user.

2:25 Self Service Data Visualization and Exploration at Genentech Research

Kiran Mukhyala, Senior Software Engineer, Bioinformatics and Computational Biology, Genentech Research and Early Development

Genomic data requires specialized infrastructure to enable data exploration and analysis at scale. We built an integrated, modular, end-to-end gene expression analysis platform implementing data import, storage, processing, analysis and visualization. The multi-layered architecture of the platform supports general, high-level applications for self-service analytics, as well as infrastructure for prototyping, incubating and integrating scientist-driven innovations. The platform coexists with other in-house and commercial software to provide a wide range of genomic data analysis and visualization options for Research scientists.

2:55 Exploring and Visualizing Single-cell RNA Sequencing Data

Michael DeRan, PhD, Scientific Consultant, Diamond Age Data Science

Recent advances in single-cell RNA sequencing (scRNA-seq) technology have made this powerful method accessible to many researchers, but have not brought with them a clear, simple workflow for data analysis. As the number of scRNA-seq datasets has increased, so too has the number of analysis tools available; for those looking to perform their first scRNA-seq analysis the range of options can seem daunting. In working with our clients, I have had the opportunity to apply many different tools to scRNA-seq data from a variety of tissues and organisms. I have used this experience to select a set of tools that are flexible and suitable to many common scRNA-seq analysis tasks. In this talk I will introduce popular tools and methods for identifying cell populations, assessing differential expression and visualizing biological processes. I will discuss common pitfalls encountered in analyzing this data and make recommendations that anyone can use in their own analysis.

3:25 Refreshment Break in the Exhibit Hall with Poster Viewing, Meet the Experts: Bio-IT World Editorial Team, and Book Signing with Joseph Kvedar, MD, Author, The Internet of Healthy Things℠ (Book will be available for purchase onsite)

NGS APPROACHES FOR CANCER
Waterfront 3

4:00 Comparison of Different Approaches for Clinical Cancer Sequencing

Jeffrey Rosenfeld, PhD, Manager of the Biomedical Informatics Shared Resource and Assistant Professor of Pathology, Rutgers Cancer Institute of NJ

The sequencing of tumors is important for guiding the treatment of cancer patients. While it is agreed that there is a need to perform sequencing of the tumor, there are a wide variety of approaches ranging from paired whole genome tumor-normal sequencing to tumor-only small panel sequencing with many intermediate possibilities. Each of the approaches has a different cost and associated benefit. I will present a comparison of different methods and their efficacy for guiding cancer treatment.

4:30 Integrated NGS Analysis to Accelerate Disease Understanding for Drug Discovery

Helen Li, Director- Research IT – Biologics & Informatics, Eli Lilly and Company

5:00 Identification of Cancer Biomarker Genes

Maryam Nazarieh, PhD, Postdoctoral Researcher, Center for Bioinformatics, Universität des Saarlandes, Saarbrücken, Germany

Identification of biomarker genes plays a crucial role in disease detection and treatment. Computational approaches enhance the insights derived from experiments and reduce the efforts of biologists and experimentalists to identify biomarker genes which play key roles in complex diseases. This is essentially achieved through prioritizing a set of genes with certain attributes (1). Here, I propose a set of transcription factors that make the largest strongly connected component of the pluripotency network in embryonic stem cells as the global regulators that control differentiation process determining cell fate. This component can be controlled by a set of master regulatory genes.  The regulatory mechanisms underlying stem cells inspired us to formulate the problem where a set of master regulatory genes in regulatory networks is identified with two combinatorial optimization problems namely as minimum dominating set and minimum connected dominating set in weakly and strongly connected components. The developed methods were applied to regulatory cancer networks to identify disease-associated genes and anti-cancer drug targets in breast cancer and hepatocellular carcinoma.  As not all the nodes in the solutions are critical, a prioritization method was developed named TopControl to rank a set of candidate genes which relate to a certain disease based on systematic analysis of the genes that are differentially expressed in tumor and normal conditions. To this purpose, the NGS data were utilized taken from The Cancer Genome Atlas for matched tumor and normal samples of liver hepatocellular carcinoma (LIHC) and breast invasive carcinoma (BRCA) datasets. Moreover, the topological features were demonstrated in regulatory networks surrounding differentially expressed genes that were highly consistent in terms of using the output of several analysis tools. We present several web servers and software packages that are publicly available at no cost. The Cytoscape plugin of minimum connected dominating set identifies a set of key regulatory genes in a user provided regulatory network based on a heuristic approach. The ILP formulations of minimum dominating set and minimum connected dominating set return the optimal solutions for the aforementioned problems. Our source code is publicly available. The web servers TFmiR and TFmiR2 construct disease-, tissue-, process-specific networks for the sets of deregulated genes and miRNAs provided by a user. They highlight topological hotspots and offer detection of three- and four-node FFL motifs as a separate web service for both organisms mouse and human. 1) Maryam Nazarieh, Understanding regulatory mechanisms underlying stem cells helps to identify cancer biomarkers. Ph.D. thesis, Saarland University, Saarbrücken, Germany (2018).

5:30 Best of Show Awards Reception in the Exhibit Hall with Poster Viewing

Read Full Post »

Gender affects the prevalence of the cancer type, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 1: Next Generation Sequencing (NGS)

Reporter and Curator: Dr. Sudipta Saha, Ph.D.

 

Gender of a person can affect the kinds of cancer-causing mutations they develop, according to a genomic analysis spanning nearly 2,000 tumours and 28 types of cancer. The results show striking differences in the cancer-causing mutations found in people who are biologically male versus those who are biologically female — not only in the number of mutations lurking in their tumours, but also in the kinds of mutations found there.

 

Liver tumours from women were more likely to carry mutations caused by a faulty system of DNA mending called mismatch repair, for instance. And men with any type of cancer were more likely to exhibit DNA changes thought to be linked to a process that the body uses to repair DNA with two broken strands. These biases could point researchers to key biological differences in how tumours develop and evolve across sexes.

 

The data add to a growing realization that sex is important in cancer, and not only because of lifestyle differences. Lung and liver cancer, for example, are more common in men than in women — even after researchers control for disparities in smoking or alcohol consumption. The source of that bias, however, has remained unclear.

In 2014, the US National Institutes of Health began encouraging researchers to consider sex differences in preclinical research by, for example, including female animals and cell lines from women in their studies. And some studies have since found sex-linked biases in the frequency of mutations in protein-coding genes in certain cancer types, including some brain cancers and advanced melanoma.

 

But the present study is the most comprehensive study of sex differences in tumour genomes so far. It looks at mutations not only in genes that code for proteins, but also in the vast expanses of DNA that have other functions, such as controlling when genes are turned on or off. The study also compares male and female genomes across many different cancers, which can allow researchers to pick up on additional patterns of DNA mutations, in part by increasing the sample sizes.

 

Researchers analysed full genome sequences gathered by the International Cancer Genome Consortium. They looked at differences in the frequency of 174 mutations known to drive cancer, and found that some of these mutations occurred more frequently in men than in women, and vice versa. When they looked more broadly at the loss or duplication of DNA segments in the genome, they found 4,285 sex-biased genes spread across 15 chromosomes.

 

There were also differences found when some mutations seemed to arise during tumour development, suggesting that some cancers follow different evolutionary paths in men and women. Researchers also looked at particular patterns of DNA changes. Such patterns can, in some cases, reflect the source of the mutation. Tobacco smoke, for example, leaves behind a particular signature in the DNA.

 

Taken together, the results highlight the importance of accounting for sex, not only in clinical trials but also in preclinical studies. This could eventually allow researchers to pin down the sources of many of the differences found in this study. Liver cancer is roughly three times as common in men as in women in some populations, and its incidence is increasing in some countries. A better understanding of its aetiology may turn out to be really important for prevention strategies and treatments.

 

References:

 

https://www.nature.com/articles/d41586-019-00562-7?utm_source=Nature+Briefing

 

https://www.nature.com/news/policy-nih-to-balance-sex-in-cell-and-animal-studies-1.15195

 

https://www.ncbi.nlm.nih.gov/pubmed/26296643

 

https://www.biorxiv.org/content/10.1101/507939v1

 

https://www.ncbi.nlm.nih.gov/pubmed/25985759

 

Read Full Post »

Pancreatic cancer survival is determined by ratio of two enzymes, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 1: Next Generation Sequencing (NGS)

Reporter and Curator: Dr. Sudipta Saha, Ph.D.

 

Protein kinase C (PKC) isozymes function as tumor suppressors in increasing contexts. These enzymes are crucial for a number of cellular activities, including cell survival, proliferation and migration — functions that must be carefully controlled if cells get out of control and form a tumor. In contrast to oncogenic kinases, whose function is acutely regulated by transient phosphorylation, PKC is constitutively phosphorylated following biosynthesis to yield a stable, autoinhibited enzyme that is reversibly activated by second messengers. Researchers at University of California San Diego School of Medicine found that another enzyme, called PHLPP1, acts as a “proofreader” to keep careful tabs on PKC.

 

The researchers discovered that in pancreatic cancer high PHLPP1 levels lead to low PKC levels, which is associated with poor patient survival. They reported that the phosphatase PHLPP1 opposes PKC phosphorylation during maturation, leading to the degradation of aberrantly active species that do not become autoinhibited. They discovered that any time an over-active PKC is inadvertently produced, the PHLPP1 “proofreader” tags it for destruction. That means the amount of PHLPP1 in patient’s cells determines his amount of PKC and it turns out those enzyme levels are especially important in pancreatic cancer.

 

This team of researchers reversed a 30-year paradigm when they reported evidence that PKC actually suppresses, rather than promotes, tumors. For decades before this revelation, many researchers had attempted to develop drugs that inhibit PKC as a means to treat cancer. Their study implied that anti-cancer drugs would actually need to do the opposite — boost PKC activity. This study sets the stage for clinicians to one day use a pancreatic cancer patient’s PHLPP1/PKC levels as a predictor for prognosis, and for researchers to develop new therapeutic drugs that inhibit PHLPP1 and boost PKC as a means to treat the disease.

 

The ratio — high PHLPP1/low PKC — correlated with poor prognoses: no pancreatic patient with low PKC in the database survived longer than five-and-a-half years. On the flip side, 50 percent of the patients with low PHLPP1/high PKC survived longer than that. While still in the earliest stages, the researchers hope that this information might one day aid pancreatic diagnostics and treatment. The researchers are next planning to screen chemical compounds to find those that inhibit PHLPP1 and restore PKC levels in low-PKC-pancreatic cancer cells in the lab. These might form the basis of a new therapeutic drug for pancreatic cancer.

 

References:

 

https://health.ucsd.edu/news/releases/Pages/2019-03-20-two-enzymes-linked-to-pancreatic-cancer-survival.aspx?elqTrackId=b6864b278958402787f61dd7b7624666

 

https://www.ncbi.nlm.nih.gov/pubmed/30904392

 

https://www.ncbi.nlm.nih.gov/pubmed/29513138

 

https://www.ncbi.nlm.nih.gov/pubmed/18511290

 

https://www.ncbi.nlm.nih.gov/pubmed/28476658

 

https://www.ncbi.nlm.nih.gov/pubmed/28283201

 

https://www.ncbi.nlm.nih.gov/pubmed/24231509

 

https://www.ncbi.nlm.nih.gov/pubmed/28112438

 

Read Full Post »

Immunoediting can be a constant defense in the cancer landscape

Immuno-editing can be a constant defense in the cancer landscape, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 1: Next Generation Sequencing (NGS)

Reporter and Curator: Dr. Sudipta Saha, Ph.D.

 

There are many considerations in the cancer immunoediting landscape of defense and regulation in the cancer hallmark biology. The cancer hallmark biology in concert with key controls of the HLA compatibility affinity mechanisms are pivotal in architecting a unique patient-centric therapeutic application. Selection of random immune products including neoantigens, antigens, antibodies and other vital immune elements creates a high level of uncertainty and risk of undesirable immune reactions. Immunoediting is a constant process. The human innate and adaptive forces can either trigger favorable or unfavorable immunoediting features. Cancer is a multi-disease entity. There are multi-factorial initiators in a certain disease process. Namely, environmental exposures, viral and / or microbiome exposure disequilibrium, direct harm to DNA, poor immune adaptability, inherent risk and an individual’s own vibration rhythm in life.

 

When a human single cell is crippled (Deranged DNA) with mixed up molecular behavior that is the initiator of the problem. A once normal cell now transitioned into full threatening molecular time bomb. In the modeling and creation of a tumor it all begins with the singular molecular crisis and crippling of a normal human cell. At this point it is either chop suey (mixed bit responses) or a productive defensive and regulation response and posture of the immune system. Mixed bits of normal DNA, cancer-laden DNA, circulating tumor DNA, circulating normal cells, circulating tumor cells, circulating immune defense cells, circulating immune inflammatory cells forming a moiety of normal and a moiety of mess. The challenge is to scavenge the mess and amplify the normal.

 

Immunoediting is a primary push-button feature that is definitely required to be hit when it comes to initiating immune defenses against cancer and an adaptation in favor of regression. As mentioned before that the tumor microenvironment is a “mixed bit” moiety, which includes elements of the immune system that can defend against circulating cancer cells and tumor growth. Personalized (Precision-Based) cancer vaccines must become the primary form of treatment in this case. Current treatment regimens in conventional therapy destroy immune defenses and regulation and create more serious complications observed in tumor progression, metastasis and survival. Commonly resistance to chemotherapeutic agents is observed. These personalized treatments will be developed in concert with cancer hallmark analytics and immunocentrics affinity and selection mapping. This mapping will demonstrate molecular pathway interface and HLA compatibility and adaptation with patientcentricity.

References:

 

https://www.linkedin.com/pulse/immunoediting-cancer-landscape-john-catanzaro/

 

https://www.cell.com/cell/fulltext/S0092-8674(16)31609-9

 

https://www.researchgate.net/publication/309432057_Circulating_tumor_cell_clusters_What_we_know_and_what_we_expect_Review

 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190561/

 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840207/

 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593672/

 

https://www.frontiersin.org/articles/10.3389/fimmu.2018.00414/full

 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593672/

 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190561/

 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388310/

 

https://www.linkedin.com/pulse/cancer-hallmark-analytics-omics-data-pathway-studio-review-catanzaro/

 

Read Full Post »

Immunotherapy may help in glioblastoma survival

Immunotherapy may help in glioblastoma survival, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 1: Next Generation Sequencing (NGS)

Reporter and Curator: Dr. Sudipta Saha, Ph.D.

 

Glioblastoma is the most common primary malignant brain tumor in adults and is associated with poor survival. But, in a glimmer of hope, a recent study found that a drug designed to unleash the immune system helped some patients live longer. Glioblastoma powerfully suppresses the immune system, both at the site of the cancer and throughout the body, which has made it difficult to find effective treatments. Such tumors are complex and differ widely in their behavior and characteristics.

 

A small randomized, multi-institution clinical trial was conducted and led by researchers at the University of California at Los Angeles involved patients who had a recurrence of glioblastoma, the most common central nervous system cancer. The aim was to evaluate immune responses and survival following neoadjuvant and/or adjuvant therapy with pembrolizumab (checkpoint inhibitor) in 35 patients with recurrent, surgically resectable glioblastoma. Patients who were randomized to receive neoadjuvant pembrolizumab, with continued adjuvant therapy following surgery, had significantly extended overall survival compared to patients that were randomized to receive adjuvant, post-surgical programmed cell death protein 1 (PD-1) blockade alone.

 

Neoadjuvant PD-1 blockade was associated with upregulation of T cell– and interferon-γ-related gene expression, but downregulation of cell-cycle-related gene expression within the tumor, which was not seen in patients that received adjuvant therapy alone. Focal induction of programmed death-ligand 1 in the tumor microenvironment, enhanced clonal expansion of T cells, decreased PD-1 expression on peripheral blood T cells and a decreasing monocytic population was observed more frequently in the neoadjuvant group than in patients treated only in the adjuvant setting. These findings suggest that the neoadjuvant administration of PD-1 blockade enhanced both the local and systemic antitumor immune response and may represent a more efficacious approach to the treatment of this uniformly lethal brain tumor.

 

Immunotherapy has not proved to be effective against glioblastoma. This small clinical trial explored the effect of PD-1 blockade on recurrent glioblastoma in relation to the timing of administration. A total of 35 patients undergoing resection of recurrent disease were randomized to either neoadjuvant or adjuvant pembrolizumab, and surgical specimens were compared between the two groups. Interestingly, the tumoral gene expression signature varied between the two groups, such that those who received neoadjuvant pembrolizumab displayed an INF-γ gene signature suggestive of T-cell activation as well as suppression of cell-cycle signaling, possibly consistent with growth arrest. Although the study was not powered for efficacy, the group found an increase in overall survival in patients receiving neoadjuvant pembrolizumab compared with adjuvant pembrolizumab of 13.7 months versus 7.5 months, respectively.

 

In this small pilot study, neoadjuvant PD-1 blockade followed by surgical resection was associated with intratumoral T-cell activation and inhibition of tumor growth as well as longer survival. How the drug works in glioblastoma has not been totally established. The researchers speculated that giving the drug before surgery prompted T-cells within the tumor, which had been impaired, to attack the cancer and extend lives. The drug didn’t spur such anti-cancer activity after the surgery because those T-cells were removed along with the tumor. The results are very important and very promising but would need to be validated in much larger trials.

 

References:

 

https://www.washingtonpost.com/health/2019/02/11/immunotherapy-may-help-patients-with-kind-cancer-that-killed-john-mccain/?noredirect=on&utm_term=.e1b2e6fffccc

 

https://www.ncbi.nlm.nih.gov/pubmed/30742122

 

https://www.practiceupdate.com/content/neoadjuvant-anti-pd-1-immunotherapy-promotes-immune-responses-in-recurrent-gbm/79742/37/12/1

 

https://www.esmo.org/Oncology-News/Neoadjuvant-PD-1-Blockade-in-Glioblastoma

 

https://neurosciencenews.com/immunotherapy-glioblastoma-cancer-10722/

 

Read Full Post »

2019 Koch Institute Symposium – Machine Learning and Cancer, June 14, 2019, 8:00 AM-5:00 PM ET MIT Kresge Auditorium, 48 Massachusetts Ave, Cambridge, MA, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 1: Next Generation Sequencing (NGS)

eProceeding 2019 Koch Institute Symposium – 18th Annual Cancer Research Symposium – Machine Learning and Cancer, June 14, 2019, 8:00 AM-5:00 PM ET MIT Kresge Auditorium, 48 Massachusetts Ave, Cambridge, MA

Announcement

Aviva Lev-Ari, PhD, RN,

Founder and Director of LPBI Group will be in attendance covering the event in REAL TIME

@pharma_BI

@AVIVA1950

#KIsymposium

AGENDA

https://custom.cvent.com/C09E632203614BC295DA40B01F45218F/files/47a27352fc1f4eb486236a34203f6396.pdf

https://ki.mit.edu/news/symposium/2019

 

8:00–9:00 Coffee Break Registration

 

9:00 –9:10 Introductory Remarks Tyler Jacks Koch Institute, MIT Phillip Sharp Koch Institute, MIT

  • INTERDISCIPLINARY research at the interface of Cancer with other disciplines, this year CS, ML,

9:10–10:30 Machine Learning in Cancer Research: The Need and the Opportunity

Moderator: Phillip Sharp, Nobel Laureate 

  • ML and cancer @MIT over a decade under discussion, ML & Cancer in research is embryonic
  • REENGINEERING Healthcare using ML: understand disease, treating it
  • MIT Stephen A. Schwarzman College of Computing, AI and Healthcare – an MIT commitment of a $MILLION
  • COST OF DRUGS IS A THIRD IN TREATMENT — TOO HIGH,

James P. Allison MD Anderson Cancer Center, Nobel Laureate FOR CURE OF CANCER, THE ONLY ONE

Immune checkpoint blockade in cancer therapy: Historical perspective, new opportunities, and prospects for cures

  • long survival on ipilimumab – Lung cancer pleural effusion
  • CTLA-4Blockade – attenuated or Terminate Proliferation vs unrestrained Proliferation – APC
  • PD-1 – Ipi/Nivo vs. Ipi in metastatic Melanoma – 10 years survival after initial three years
  • FDA Approved CTLA-4 and Anti-PD-1 for a dozen indication
  • CD4, CD8, NKT – CHeckpoint blockage modulates MC38 infiltrating T cell population frequency
  • Cellular mechanism interaction
  • T cell differentiation is complex – negative costimulation regulate T cell differentiation
  • comprehensive profiling of peripheral T cell arising
  • Expansion of phynotype – distinct gene expression
  • Transcription loss of PD-1 expands CD8 T cells
  • Nuanced Model – T cell differentiation
  • Role of T cells in Immunotherapy

Aviv Regev Broad Institute; Koch Institute, MIT

Cell atlases as roadmaps to cancer

  • Experimental data and computation data
  • Tumors: a complex cellular ecosystem
  • Genetic pathology, Combination therapy Genetic variants and
  • Components vs Programs (regulatory, pathways, tissue modules, disease road map)
  • ML Applications: Immunotherapy in melanoma
  • Learning an single cell profiling and spatial organization – massively parallel cell profiling
  • malignant cells from T cell cold tumors
  • T cell T cell CD8 Malignant: Resistant
  • Computational search predicts CDK4/6 as program regulators
  • the resistance program is reversed abemaciclib sensitized to B16
  • Resistance to immunotherapy in Melanoma
  • Generalize across types of cancers – Resistance to treatment
  • Atlas for Synovial sarcoma has anti-tumor activity in its immune environment
  • Melanoma vs Synovial sarcoma (SS18-SSX fusion directly controls the core oncogenic program
  • Target the core oncogenic program therapeutically
  • IFN from CD8 T NF repress the program
  • Insi2Vec: Define a cell by intrinsic and extrinsic and spatial features: generalize across patient samples in melanoma
  • Identifying key patio-molecular archetypes
  • Expanding to full Transcriptome
  • Emerging toolbox for spatial genomics: Protein, RNA,
  • Compressed sensing,

Regina Barzilay MIT Computer Science and Artificial Intelligence Laboratory; Koch Institute,

MIT How machine learning changes cancer research

  • ML & Clinical Oncology
  • Data Science perspective – Raw Data to Cure: Extract information
  • NLP – penetration of deepLearning @MGH
  • Drug discovery – New molecules
  • MIT – ML in drug discovery
  • Risk models: age, family history, prior breast procedures breast density
  • High risk and Breast density
  • Myth #1: DEMOCRATIZATION OF AI – deep learning and customization
  • Myth @2: Bias – Deep Learning allows across population studies
  • Myth #3: Black-Box Architecture 0 @MIT Interpretable models
  • J-Clinic @MIT – ML and Healthcare Hospitals are recruited to use the algorithms

11:00–12:25 Machine Learning to Decipher Cellular and Molecular Mechanisms in Cancer

Moderator: Matthew Vander

Heiden Michael Angelo Stanford University

Comprehensive enumeration of immune cells in solid tumors using Multiplexed ion beam imaging (MIBI)

  • Tissue imaging – high dimensional, multiplexing: high sensitivity, dynamic range,
  • GI Tissue selection – Immunofluorescence (IF)  fluorophores – elemental reporters and mass spectrometry  Label antibody,
  • Immune populations in triple negative breast cancer
  • Patient stratification survival
  • mixed tumor: Immune cells, non immune cells – response to PD-1
  • Single cell: imaging data trained by nuclear interior ( nuclei only, , segmentation channel using DeepCell v1.0
  • TB granulomas,
  • Cell type identification with deep learning – No downstream
  • 3D Segmentation Melanoma
  • Assays and Ion sources

Olga Troyanskaya Princeton University

Decoding cancer genomes with deep learning

  • genome to phenotype – BIG genomics data to understand human disease
  • exosome – non coding region
  • gene regulation affected by genome for gene expression
  • sequence specific
  • Interpreting a genome: predicting the effect of any mutation: coding variant vs non-coding variance – regulatory code, transcription marks, DeepSEA – model learns from one genome interactions of biochemical level models, variants motives cell type
  • Interpreting a Genome: predicting the effect of any mutation: Noncoding variant effect in ASD from WGS data
  • DeNovo mutations: How impactful are these mutations in Autism patients – to % not explained by sequencing
  • DeepSEA identifies significant noncoding regulatory mutation burden in ASD
  • Cell-type specific expression models capture tissue-specific
  • ExPecto-prioritized putative casual GWAS variants
  • HumanBase Networks best model selected are

Dana Pe’er Sloan Kettering Institute

Manifolds underlying plasticity in development, regeneration and cancer

  • Asynchronous Nature of Cells
  • Single cell transitional states, homeostatic
  • Representing population structure as a neighbor graph: each node is a cell connected to a neighborhood – diffusion components Magic: Using structure for data recovery
  • PALANTIR: a probabilistic model for cell fate
  • Learn differentiation trajectories/pseudo-time ordering
  • Computing Differentiation probabilities stochastic process – branch
  • The gut tube comprises cells of two distinct regions
  • mammal cell plasticity – endodermal organ identities in space
  • VE cells express key organ lineage regulators similarly to DE cell
  • Uncovering unappreciated lineage relationship
  • Lung adenocarcinoma – tumor – 10% are cancer cell the rest are not therefore – they are ORGANS
  • Primary tumor exhibit epithelial progenitor cells
  • Pancreatic Ductal Adenocarcinoma – ductal Metaplasia
  • Immune ecosystem reprogrammed
  • Leptomeningeal niche — iron binding – adopt environment and prevent iron from the immune system
  • Tumor plasticity – Mutation Kras + injury to cause pancreatic cancer

 

Peter Sorger Harvard Medical School

Measuring and modeling variability in drug response in cells, tissues and clinical trials

  • combination therapy and drug synergy
  • Re-digitalization of 300 clinical trials
  • combination immunotherapy: Assumption each patient benefits from both = synergy
  • vs the assumption of NO interaction: each Patient benefit from ONE or the Other
  • Novartis PDX models
  • Gastric Cancer PDXs
  • Three way combination drug therapy – a deeper look at RAF and MEK inhibitors in BRAF mutant melanoma
  • Pharmacology of ‘reconstituted pulses” independent action
  • Heterogeneous response – sophisticated stratification of patients Four biopsy vs Three Biopsy
  • Highly multiplexed, high resolution image of FFPE specimens
  • Assaying the effects of multiple possible
  • Cancer Precision Medicine per NCI
  • Precision medicine based on therapeutic response at sisngel cell level
  • Pharmacological synergy is over emphsized – time sensitivity prevent the interactions expected

12:30–2:00 Lunch Break

2:00–3:00 Big Data, Computation and the Future of Health Care

Moderator: Susan Hockfield

Jay Bradner Novartis Institutes for BioMedical Research

  • AI is a Tool in all phases of drug discovery integrated analysis of epigenetics
  • strategy for investment in 400 Scientists, big data
  • monitoring of Clinical Trial around the  World
  • generative chemistry – 100 years of discovery in chemistry
  • validation models – bring trials to patients – distributed model of participation
  • catalyst – ML in biological experimentation
  • Published 700 articles per year at Novartis by 400 scientists
  • Population Data sets
  • IN 5 YEARS MASSIVE data will dominate molecule selection in Drug delivery

Aine Hanly VP Amgen

  • 17% improvement in survival rate in 50 years
  • Data infrastructure investment paid off
  • Partnerships, interoperability in EMR

Clifford Hudis American Society of Clinical Oncology (ASCO)

  • 75% of communication is by FAX still
  • White cell data count – convert data structure on EMR
  • Data in the Cloud for sharing
  • 165 Million in US — employer covers health cost
  • ACCESS to 2,000 clinical trials for repurposing

Constance Lehman Massachusetts General Hospital

  • Pathway – Screening mammograms is run via the algorithm, report generated, Radiologist accept or reject the mobile presented
  • more domains need AI and specialties of Medicine
  • Development and implementation then dissemination to multiple sites
  • In 1000 mammogram only 8 cancers detected

David Schenkein GOOGLE Venture (GV)

  • Regeneron, Geisinger Health System, Amgen – Big data repositories are built
  • Clinical Trials and big data
  • delivery side: AI: Pathology and Radiology, early diagnostics:
  • AI in MDs Offices to record the entire sessions
  • diagnostics – Foundation Medicine diagnostics had difficult time to prove improvement to justify reimbursement

 

3:00–3:15 Break

 

3:15–4:40 Machine Learning into the Clinic

 

Moderator: Sangeeta Bhatia, Koch Institute, MIT

Tommi S. Jaakkola MIT Computer Science and Artificial Intelligence Laboratory

Machine learning for drug design

  • Automation arises from data
  • How much data is enough? assay size vs all spectrum
  • MIT Consortium on Drug Discovery: 13 Pharma, chemistry Department, Chemical Engineering Department, CSMIT Consortium on Pharmaceutical Discovery
  • multi-resolution representations
  • substructures with precision attachment – what atoms are underlined
  • predicting molecular properties
  • programmatic optimization – machine translation problem in analogy – learn the mapping principles from examples
  • Example comparisons – Programmatic optimization – Success %
  • Understanding: Accuracy- interpretable, statistical constraints inserted
  • integrations with biology and cancer research
  • Automating Drug Design – learn from exampl

Andrew Beck PathAI

Artificial intelligence for pathology: From discovery to AI-powered companion diagnostics

  • Pathologic diagnosis informs all subsequent medical decisions
  • Discordance among pathologists is common in interpretation of breast biopsy
  • Discordance among pathologists is common in interpretation of skin biopsy – melanoma
  • Discordance among pathologists is common in interpretation across all fields: NSCLC, bladder,
  • AI – deep learning is driving major advances in computer vision
  • Reduce errors training set vs validation set
  • computer vision vs Human eye – machine learning is BETTER
  • Labeled and counting data standardization requires work with the community of Pathologists
  • Automatic interpretation of cells and tissues
  • Immuno-oncology
  • TisSue and cellular phenologies – Pathological phenotypes
  • BMS – CD8 continuum – Phenotype : Identify stromal and parenchymal CD8 infalmmation
  • AI project with Novartis

Brian Wolpin Dana-Farber Cancer Institute

Early detection of pancreatic cancer

  • ML for Pancreatic Cancer Early detection
  • Metabolic alterations: Muscle wasting, subcutaneous adipose
  • Automated Peripheral Tissue Segmentation
  • 30,000 scans: changes by race, age, : Image-Based Risk Modeling within Large Health Systems

longitudinal Cohorts: Risk Factors

  • Diabetes related to pancreatic cancer
  • risk for weight and Diabetes
  • Medication: Start and Stopped: NSAIDs, Tylenol, H2 Blocker, PPI, anti- HTN,
  • ML – early detection: altered systemic metabolism

Stephen Friend University of Oxford

From complex to complicated problems: What are the known unknowns, and unknown unknowns in using wearables to forecast symptom transitions

  • Pattern recognition for prognosis NEJM 20 years took since Breast cancer started to benefit from pattern recognition
  • Participants-Centered
  • 10M smart watches
  • APPLE – many studies Smart watch – 15,000 participants donate data via their watch – large scale ALERT based on data analysis
  • Inter-individual Diversity
  • Personal Health Assistant
  • all day sensing & recording
  • Health Assessment – signals to Symptoms
  • Deep Learning – multiple stages of non-linear feature transformation
  • Vector Institute – data analysis was done [Pregnancy]
  • Forecasting – binary labels: Well or Sick, intra and inter-individual longitudinal
  • 4YouandMe  – Foundation
  • Wearables for Cancer patients

4:40–4:45 Closing Remarks Phillip Sharp Koch Institute, MIT

 

 

Machine Learning and Cancer

The 18th Annual Koch Institute Summer Symposium on June 14, 2019 at MIT’s Kresge Auditorium will focus on Machine Learning and Cancer.

Both fields are undergoing dramatic changes, and their integration holds great promise for cancer research, diagnostics, and therapeutics. Cancer treatment and research have advanced rapidly with an increasing reliance on data-driven decisions. The volume, complexity, and diversity of research and clinical data—from genomics and single-cell molecular and image-based profiles to histopathology, clinical imaging, and medical records—far surpasses the capacity of individual scientists and physicians. However, they offer a remarkable opportunity to new approaches for data science and machine learning to provide holistic and intelligible interpretations to trained experts and patients alike. These advances will make it possible to provide far better diagnostics, discover possible chemical pathways for de novo synthesis of therapeutic compounds, predict accurately the risk of individuals for development of specific cancers years before metastatic spread, and determine the combination of agents that will stimulate immune rejection of a tumor or selectively induce the death of all cells in a tumor.

The symposium will address these issues through three sessions:

  • Machine Learning in Cancer Research: the Need and the Opportunity
  • Machine Learning to Decipher Cellular and Molecular Mechanisms in Cancer
  • Machine Learning into the Clinic

Sessions will be followed by a panel discussion of broadly informed experts moderated by MIT President Emerita Susan Hockfield.

Introductory remarks will be given by symposium co-chairs and Koch Institute faculty members Regina Barzilay, Aviv Regev and Phillip Sharp.

 

Keynote Speakers | Machine Learning in Cancer Research: the Need and the Opportunity

James P. Allison, PhD

MD Anderson Cancer Center

Regina Barzilay, PhD

MIT Computer Science and Artificial Intelligence Lab, Koch Institute for Integrative Cancer Research at MIT

Aviv Regev, PhD

Broad Institute, Koch Institute for Integrative Cancer Research at MIT

 

Session Speakers

Michael R. Angelo, MD, PhD

Stanford Unviersity

Andrew Beck

PathAI

Stephen H. Friend, MD, PhD

Sage Bionetworks

Tommi Jaakkola, PhD

MIT Computer Science and Artificial Intelligence Lab

Dana Pe’er, PhD

Memorial Sloan Kettering Cancer Center

Peter Sorger, PhD

Harvard Medical School

Olga Troyanskaya, PhD

Princeton University

Brian Wolpin, MD

Dana-Farber Cancer Institute

 

Panel Discussion | Big Data, Computation and the Future of Health Care

James (Jay) Bradner, MD

Novartis

Clifford A. Hudis, MD

American Society of Clinical Oncology

Constance D. Lehman, MD, PhD

Massachusetts General Hospital

Norman (Ned) Sharpless, MD

National Cancer Institute

 

Moderator: Susan Hockfield, PhD

Koch Institute for Integrative Cancer Research at MIT

[if gte mso 9]>

SOURCE

From: 2019 Koch Institute Symposium <ki-events@mit.edu>

Reply-To: <ki-events@mit.edu>

Date: Tuesday, March 12, 2019 at 11:30 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Invitation to the 2019 Koch Institute Symposium – Machine Learning and Cancer

Read Full Post »

Hypertriglyceridemia: Evaluation and Treatment Guideline

Reporter and Curator: Dr. Sudipta Saha, Ph.D.

 

Severe and very severe hypertriglyceridemia increase the risk for pancreatitis, whereas mild or moderate hypertriglyceridemia may be a risk factor for cardiovascular disease. Individuals found to have any elevation of fasting triglycerides should be evaluated for secondary causes of hyperlipidemia including endocrine conditions and medications. Patients with primary hypertriglyceridemia must be assessed for other cardiovascular risk factors, such as central obesity, hypertension, abnormalities of glucose metabolism, and liver dysfunction. The aim of this study was to develop clinical practice guidelines on hypertriglyceridemia.

The diagnosis of hypertriglyceridemia should be based on fasting levels, that mild and moderate hypertriglyceridemia (triglycerides of 150–999 mg/dl) be diagnosed to aid in the evaluation of cardiovascular risk, and that severe and very severe hypertriglyceridemia (triglycerides of >1000 mg/dl) be considered a risk for pancreatitis. The patients with hypertriglyceridemia must be evaluated for secondary causes of hyperlipidemia and that subjects with primary hypertriglyceridemia be evaluated for family history of dyslipidemia and cardiovascular disease.

The treatment goal in patients with moderate hypertriglyceridemia should be a non-high-density lipoprotein cholesterol level in agreement with National Cholesterol Education Program Adult Treatment Panel guidelines. The initial treatment should be lifestyle therapy; a combination of diet modification, physical activity and drug therapy may also be considered. In patients with severe or very severe hypertriglyceridemia, a fibrate can be used as a first-line agent for reduction of triglycerides in patients at risk for triglyceride-induced pancreatitis.

Three drug classes (fibrates, niacin, n-3 fatty acids) alone or in combination with statins may be considered as treatment options in patients with moderate to severe triglyceride levels. Statins are not be used as monotherapy for severe or very severe hypertriglyceridemia. However, statins may be useful for the treatment of moderate hypertriglyceridemia when indicated to modify cardiovascular risk.

 

References:

 

https://www.medpagetoday.com/clinical-connection/cardio-endo/77242?xid=NL_CardioEndoConnection_2019-01-21

https://www.ncbi.nlm.nih.gov/pubmed/19307519

https://www.ncbi.nlm.nih.gov/pubmed/23009776

https://www.ncbi.nlm.nih.gov/pubmed/6827992

https://www.ncbi.nlm.nih.gov/pubmed/22463676

https://www.ncbi.nlm.nih.gov/pubmed/17635890

 

Read Full Post »

37th Annual J.P. Morgan HEALTHCARE CONFERENCE: News at #JPM2019 for Jan. 10, 2019: Deals and Announcements

Reporter: Stephen J. Williams, Ph.D.

From Biospace.com

 

JP Morgan Healthcare Conference Update: Sage, Mersana, Shutdown Woes and Babies

Speaker presenting to audience at a conference

With the J.P. Morgan Healthcare Conference winding down, companies remain busy striking deals and informing investors about pipeline advances. BioSpace snagged some of the interesting news bits to come out of the conference from Wednesday.

SAGE Therapeutics – Following a positive Phase III report that its postpartum depression treatment candidate SAGE-217 hit the mark in its late-stage clinical trial, Sage Therapeutics is eying the potential to have multiple treatment options available for patients. At the start of J.P. Morgan, Sage said that patients treated with SAGE-217 had a statistically significant improvement of 17.8 points in the Hamilton Rating Scale for Depression, compared to 13.6 for placebo. The company plans to seek approval for SAGE-2017, but before that, the FDA is expected to make a decision on Zulresso in March. Zulresso already passed muster from advisory committees in November, and if approved, would be the first drug specifically for postpartum depression. In an interview with the Business Journal, Chief Business Officer Mike Cloonan said the company believes there is room in the market for both medications, particularly since the medications address different patient populations.

 

Mersana Therapeutics – After a breakup with Takeda Pharmaceutical and the shelving of its lead product, Cambridge, Mass.-based Mersana is making a new path. Even though a partial clinical hold was lifted following the death of a patient the company opted to shelve development of XMT-1522. During a presentation at JPM, CEO Anna Protopapas noted that many other companies are developing therapies that target the HER2 protein, which led to the decision, according to the Boston Business Journal. Protopapas said the HER2 space is highly competitive and now the company will focus on its other asset, XMT-1536, an ADC targeting NaPi2b, an antigen highly expressed in the majority of non-squamous NSCLC and epithelial ovarian cancer. XMT-1536 is currently in Phase 1 clinical trials for NaPi2b-expressing cancers, including ovarian cancer, non-small cell lung cancer and other cancers. Data on XMT-1536 is expected in the first half of 2019.

Novavax – During a JPM presentation, Stan Erck, CEO of Novavax, pointed to the company’s RSV vaccine, which is in late-stage development. The vaccine is being developed for the mother, in order to protect an infant. The mother transfers the antibodies to the infant, which will provide the baby with protection from RSV in its first six months. Erck called the program historic. He said the Phase III program is in its fourth year and the company has vaccinated 4,636 women. He said they are tracking the women and the babies. Researchers call the mothers every week through the first six months of the baby’s life to acquire data. Erck said the company anticipates announcing trial data this quarter. If approved, Erck said the market for the vaccine could be a significant revenue driver.

“You have 3.9 million birth cohorts and we expect 80 percent to 90 percent of those mothers to be vaccinated as a pediatric vaccine and in the U.S. the market rate is somewhere between $750 million and a $1 billion and then double that for worldwide market. So it’s a large market and we will be first to market in this,” Erck said, according to a transcript of the presentation.

Denali Therapeutics – Denali forged a collaboration with Germany-based SIRION Biotech to develop gene therapies for central nervous disorders. The two companies plan to develop adeno-associated virus (AAV) vectors to enable therapeutics to cross the blood-brain barrier for clinical applications in neurodegenerative diseases including Parkinson’s, Alzheimer’s disease, ALS and certain other diseases of the CNS.

AstraZeneca – Pharma giant AstraZeneca reported that in 2019 net prices on average across the portfolio will decrease versus 2018. With a backdrop of intense public and government scrutiny over pricing, Market Access head Rick Suarez said the company is increasing its pricing transparency. Additionally, he said the company is looking at new ways to price drugs, such as value-based reimbursement agreements with payers, Pink Sheet reported.

Amarin Corporation – As the company eyes a potential label expansion approval for its cardiovascular disease treatment Vascepa, Amarin Corporation has been proactively hiring hundreds of sales reps. In the fourth quarter, the company hired 265 new sales reps, giving the company a sales team of more than 400, CEO John Thero said. Thero noted that is a label expansion is granted by the FDA, “revenues will increase at least 50 percent over what we did in the prior year, which would give us revenues of approximate $350 million in 2019.”

Government Woes – As the partial government shutdown in the United States continues into its third week, biotech leaders at JPM raised concern as the FDA’s carryover funds are dwindling. With no new funding coming in, reviews of New Drug Applications won’t be able to continue past February, Pink Sheet said. While reviews are currently ongoing, no New Drug Applications are being accepted by the FDA at this time. With the halt of NDA applications, that has also caused some companies to delay plans for an initial public offering. It’s hard to raise potential investor excitement without the regulatory support of a potential drug approval. During a panel discussion, Jonathan Leff, a partner at Deerfield Management, noted that the ongoing government shutdown is a reminder of how “overwhelmingly dependent the whole industry of biotech and drug development is on government,” Pink Sheet said.

Other posts on the JP Morgan 2019 Healthcare Conference on this Open Access Journal include:

#JPM19 Conference: Lilly Announces Agreement To Acquire Loxo Oncology

36th Annual J.P. Morgan HEALTHCARE CONFERENCE January 8 – 11, 2018

37th Annual J.P. Morgan HEALTHCARE CONFERENCE: #JPM2019 for Jan. 8, 2019; Opening Videos, Novartis expands Cell Therapies, January 7 – 10, 2019, Westin St. Francis Hotel | San Francisco, California

37th Annual J.P. Morgan HEALTHCARE CONFERENCE: News at #JPM2019 for Jan. 8, 2019: Deals and Announcements

 

Read Full Post »

#JPM19 Conference: Lilly Announces Agreement To Acquire Loxo Oncology, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 1: Next Generation Sequencing (NGS)

#JPM19 Conference: Lilly Announces Agreement To Acquire Loxo Oncology

Reporter: Gail S. Thornton

 

News announced during the 37th J.P. Morgan Healthcare Conference (#JPM19): Drugmaker Eli Lilly and Company announced its plans to acquire Loxo for $8 billion, as part of its oncology strategy, which focuses  “opportunities for first-in-class and best-in-class therapies.”   

 

Please read their press release below.


INDIANAPOLIS and STAMFORD, Conn., Jan. 7, 2019 /PRNewswire/ —

  • Acquisition will broaden the scope of Lilly’s oncology portfolio into precision medicines through the addition of a marketed therapy and a pipeline of highly selective potential medicines for patients with genomically defined cancers.
  • Loxo Oncology’s pipeline includes LOXO-292, an oral RET inhibitor being studied across multiple tumor types, which recently was granted Breakthrough Therapy designation by the FDA and could launch in 2020.
  • Loxo Oncology’s Vitrakvi® (larotrectinib) is an oral TRK inhibitor developed and commercialized in collaboration with Bayer that was recently approved by the FDA.
  • Lilly will commence a tender offer to acquire all outstanding shares of Loxo Oncology for a purchase price of$235.00 per share in cash, or approximately $8.0 billion.
  • Lilly will conduct a conference call with the investment community and media today at 8:45 a.m. EST.

Eli Lilly and Company (NYSE: LLY) and Loxo Oncology, Inc. (NASDAQ: LOXO) today announced a definitive agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash, or approximately $8.0 billion. Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers.

The acquisition would be the largest and latest in a series of transactions Lilly has conducted to broaden its cancer treatment efforts with externally sourced opportunities for first-in-class and best-in-class therapies. Loxo Oncology is developing a pipeline of targeted medicines focused on cancers that are uniquely dependent on single gene abnormalities that can be detected by genomic testing.  For patients with cancers that harbor these genomic alterations, a targeted medicine could have the potential to treat the cancer with dramatic effect.

Loxo Oncology has a promising portfolio of approved and investigational medicines, including:

  • LOXO-292, a first-in-class oral RET inhibitor that has been granted Breakthrough Therapy designation by the FDA for three indications, with an initial potential launch in 2020.  LOXO-292 targets cancers with alterations to the rearranged during transfection (RET) kinase. RET fusions and mutations occur across multiple tumor types, including certain lung and thyroid cancers as well as a subset of other cancers.
  • LOXO-305, an oral BTK inhibitor currently in Phase 1/2. LOXO-305 targets cancers with alterations to the Bruton’s tyrosine kinase (BTK), and is designed to address acquired resistance to currently available BTK inhibitors. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas.
  • Vitrakvi, a first-in-class oral TRK inhibitor developed and commercialized in collaboration with Bayer that was recently approved by the U.S. Food and Drug Administration (FDA). Vitrakvi is the first treatment that targets a specific genetic abnormality to receive a tumor-agnostic indication at the time of initial FDA approval.
  • LOXO-195, a follow-on TRK inhibitor also being studied by Loxo Oncology and Bayer for acquired resistance to TRK inhibition, with a potential launch in 2022.

“Using tailored medicines to target key tumor dependencies offers an increasingly robust approach to cancer treatment,” said Daniel Skovronsky, M.D., Ph.D., Lilly’s chief scientific officer and president of Lilly Research Laboratories. “Loxo Oncology’s portfolio of RET, BTK and TRK inhibitors targeted specifically to patients with mutations or fusions in these genes, in combination with advanced diagnostics that allow us to know exactly which patients may benefit, creates new opportunities to improve the lives of people with advanced cancer.”

“We are gratified that Lilly has recognized our contributions to the field of precision medicine and are excited to see our pipeline benefit from the resources and global reach of the Lilly organization,” said Josh Bilenker, M.D., chief executive officer of Loxo Oncology. “Tumor genomic profiling is becoming standard-of-care, and it will be critical to continue innovating against new targets, while anticipating mechanisms of resistance to available therapies, so that patients with advanced cancer have the chance to live longer and better lives.”

“Lilly Oncology is committed to developing innovative, breakthrough medicines that will make a meaningful difference for people with cancer and help them live longer, healthier lives,” said Anne White, president of Lilly Oncology. “The acquisition of Loxo Oncology represents an exciting and immediate opportunity to expand the breadth of our portfolio into precision medicines and target cancers that are caused by specific gene abnormalities. The ability to target tumor dependencies in these populations is a key part of our Lilly Oncology strategy. We look forward to continuing to advance the pioneering scientific innovation begun by Loxo Oncology.”

“We are excited to have reached this agreement with a team that shares our commitment to ensuring that emerging translational science reaches patients in need,” said Jacob Van Naarden, chief operating officer of Loxo Oncology. “We are confident that the work we have started, which includes an FDA approved drug, and a pipeline spanning from Phase 2 to discovery, will continue to thrive in Lilly’s hands.”

Under the terms of the agreement, Lilly will commence a tender offer to acquire all outstanding shares of Loxo Oncology for a purchase price of $235.00 per share in cash, or approximately $8.0 billion. The transaction is not subject to any financing condition and is expected to close by the end of the first quarter of 2019, subject to customary closing conditions, including receipt of required regulatory approvals and the tender of a majority of the outstanding shares of Loxo Oncology’s common stock. Following the successful closing of the tender offer, Lilly will acquire any shares of Loxo Oncology that are not tendered into the tender offer through a second-step merger at the tender offer price.

The tender offer represents a premium of approximately 68 percent to Loxo Oncology’s closing stock price on January 4, 2019, the last trading day before the announcement of the transaction. Loxo Oncology’s board recommends that Loxo Oncology’s shareholders tender their shares in the tender offer.  Additionally, a Loxo Oncology shareholder, beneficially owning approximately 6.6 percent of Loxo Oncology’s outstanding common stock, has agreed to tender its shares in the tender offer.

This transaction will be reflected in Lilly’s financial results and financial guidance according to Generally Accepted Accounting Principles (GAAP). Lilly will provide an update to its 2019 financial guidance, including the expected impact from the acquisition of Loxo Oncology, as part of its fourth-quarter and full-year 2018 financial results announcement on February 13, 2019.

For Lilly, Deutsche Bank is acting as the exclusive financial advisor and Weil, Gotshal & Manges LLP is acting as legal advisor in this transaction. For Loxo Oncology, Goldman Sachs & Co. LLC is acting as exclusive financial advisor and Fenwick & West LLP is acting as legal advisor.

Conference Call and Webcast
Lilly will conduct a conference call with the investment community and media today at 8:45 a.m. EST to discuss the acquisition of Loxo Oncology.  Investors, media and the general public can access a live webcast of the conference call through the Webcasts & Presentations link that will be posted on Lilly’s website at www.lilly.com.  The webcast of the conference call will be available for replay through February 7, 2019.

About LOXO-292
LOXO-292 is an oral and selective investigational new drug in clinical development for the treatment of patients with cancers that harbor abnormalities in the rearranged during transfection (RET) kinase. RET fusions and mutations occur across multiple tumor types with varying frequency. LOXO-292 was designed to inhibit native RET signaling as well as anticipated acquired resistance mechanisms that could otherwise limit the activity of this therapeutic approach. LOXO-292 has been granted Breakthrough Therapy Designation by the U.S. FDA for three indications, and could launch as early as 2020.

About LOXO-305
LOXO-305 is an investigational, highly selective non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells. BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including chronic lymphocytic leukemia, Waldenstrom’s macroglobulinemia, mantle cell lymphoma and marginal zone lymphoma.

About Vitrakvi® (larotrectinib)
Vitrakvi is an oral TRK inhibitor for the treatment of adult and pediatric patients with solid tumors with a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation that are either metastatic or where surgical resection will likely result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

About LOXO-195
LOXO-195 is a selective TRK inhibitor that is being investigated to address potential mechanisms of acquired resistance that may emerge in patients receiving Vitrakvi® (larotrectinib) or other multikinase inhibitors with anti-TRK activity.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/newsroom/social-channels. C-LLY

About Loxo Oncology
Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, with the intention of delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company’s website at http://www.loxooncology.com.

Lilly Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements about the benefits of Lilly’s acquisition of Loxo Oncology, Inc. (“Loxo Oncology”). It reflects Lilly‘s current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in implementing the transaction and in drug development. Among other things, there can be no guarantee that the transaction will be completed in the anticipated timeframe, or at all, or that the conditions required to complete the transaction will be met, that Lilly will realize the expected benefits of the transaction, that the molecules will be approved on the anticipated timeline or at all, or that the potential products will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly‘s most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission (“the SEC”). Lilly will provide an update to certain elements of its 2019 financial guidance as part of its fourth quarter and full-year 2018 financial results announcement. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Loxo Oncology Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” relating to the acquisition of Loxo Oncology by Lilly. Such forward-looking statements include the ability of Loxo Oncology and Lilly to complete the transactions contemplated by the merger agreement, including the parties’ ability to satisfy the conditions to the consummation of the offer and the other conditions set forth in the merger agreement and the possibility of any termination of the merger agreement, as well as the role of targeted genomics and diagnostics in oncology treatment and acceleration of our work in developing medicines. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Actual results may differ materially from current expectations because of risks associated with uncertainties as to the timing of the offer and the subsequent merger; uncertainties as to how many of Loxo Oncology’s stockholders will tender their shares in the offer; the risk that competing offers or acquisition proposals will be made; the possibility that various conditions to the consummation of the offer or the merger may not be satisfied or waived; the effects of disruption from the transactions contemplated by the merger agreement on Loxo Oncology’s business and the fact that the announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the risk that stockholder litigation in connection with the offer or the merger may result in significant costs of defense, indemnification and liability; other uncertainties pertaining to the business of Loxo Oncology, including those set forth in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Loxo Oncology’s Annual Report on Form 10-K for the year ended December 31, 2017, which is on file with the SEC and available on the SEC’s website at www.sec.gov. Additional factors may be set forth in those sections of Loxo Oncology’s Quarterly Report on Form 10-Q for the quarter endedSeptember 30, 2018, filed with the SEC in the fourth quarter of 2018.  In addition to the risks described above and in Loxo Oncology’s other filings with the SEC, other unknown or unpredictable factors could also affect Loxo Oncology’s results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information contained in this press release is provided only as of the date of this report, and Loxo Oncology undertakes no obligation to update any forward-looking statements either contained in or incorporated by reference into this report on account of new information, future events, or otherwise, except as required by law.

Additional Information about the Acquisition and Where to Find It

The tender offer for the outstanding shares of Loxo Oncology referenced in this communication has not yet commenced. This announcement is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of Loxo Oncology, nor is it a substitute for the tender offer materials that Lilly and its acquisition subsidiary will file with the SEC upon commencement of the tender offer. At the time the tender offer is commenced, Lilly and its acquisition subsidiary will file tender offer materials on Schedule TO, and Loxo Oncology will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION. HOLDERS OF SHARES OF LOXO ONCOLOGY ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF LOXO ONCOLOGY SECURITIES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SECURITIES. The Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, will be made available to all holders of shares of Loxo Oncology at no expense to them. The tender offer materials and the Solicitation/Recommendation Statement will be made available for free at the SEC’s web site at www.sec.gov. 

In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Lilly and Loxo Oncology file annual, quarterly and special reports and other information with the SEC.  You may read and copy any reports or other information filed by Lilly or Loxo Oncology at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the Commission at 1-800-SEC-0330 for further information on the public reference room.  Lilly’s and Loxo Oncology’s filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.

SOURCE

Eli Lilly and Company – https://www.lilly.com

Other related articles published in this Open Access Online Scientific Journal include the following:

2017

FDA has approved the world’s first CAR-T therapy, Novartis for Kymriah (tisagenlecleucel) and Gilead’s $12 billion buy of Kite Pharma, no approved drug and Canakinumab for Lung Cancer (may be?)

https://pharmaceuticalintelligence.com/2017/08/30/fda-has-approved-the-worlds-first-car-t-therapy-novartis-for-kymriah-tisagenlecleucel-and-gileads-12-billion-buy-of-kite-pharma-no-approved-drug-and-canakinumab-for-lung-cancer-may-be/

2016

Pioneers of Cancer Cell Therapy:  Turbocharging the Immune System to Battle Cancer Cells — Success in Hematological Cancers vs. Solid Tumors

https://pharmaceuticalintelligence.com/2016/08/19/pioneers-of-cancer-cell-therapy-turbocharging-the-immune-system-to-battle-cancer-cells-success-in-hematological-cancers-vs-solid-tumors/

2015

Personalized Medicine – The California Initiative

https://pharmaceuticalintelligence.com/2015/10/12/personalized-medicine/

2013

Volume One: Genomics Orientations for Personalized Medicine

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-one-genomics-orientations-for-personalized-medicine/

Read Full Post »

Role of Informatics in Precision Medicine: Notes from Boston Healthcare Webinar: Can It Drive the Next Cost Efficiencies in Oncology Care? Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 1: Next Generation Sequencing (NGS)

Role of Informatics in Precision Medicine: Notes from Boston Healthcare Webinar: Can It Drive the Next Cost Efficiencies in Oncology Care?

Reporter: Stephen J. Williams, Ph.D.

 

Boston Healthcare sponsored a Webinar recently entitled ” Role of Informatics in Precision Medicine: Implications for Innovators”.  The webinar focused on the different informatic needs along the Oncology Care value chain from drug discovery through clinicians, C-suite executives and payers. The presentation, by Joseph Ferrara and Mark Girardi, discussed the specific informatics needs and deficiencies experienced by all players in oncology care and how innovators in this space could create value. The final part of the webinar discussed artificial intelligence and the role in cancer informatics.

 

Below is the mp4 video and audio for this webinar.  Notes on each of the slides with a few representative slides are also given below:

Please click below for the mp4 of the webinar:

 

 


  • worldwide oncology related care to increase by 40% in 2020
  • big movement to participatory care: moving decision making to the patient. Need for information
  • cost components focused on clinical action
  • use informatics before clinical stage might add value to cost chain

 

 

 

 

Key unmet needs from perspectives of different players in oncology care where informatics may help in decision making

 

 

 

  1.   Needs of Clinicians

– informatic needs for clinical enrollment

– informatic needs for obtaining drug access/newer therapies

2.  Needs of C-suite/health system executives

– informatic needs to help focus of quality of care

– informatic needs to determine health outcomes/metrics

3.  Needs of Payers

– informatic needs to determine quality metrics and managing costs

– informatics needs to form guidelines

– informatics needs to determine if biomarkers are used consistently and properly

– population level data analytics

 

 

 

 

 

 

 

 

 

 

 

 

What are the kind of value innovations that tech entrepreneurs need to create in this space? Two areas/problems need to be solved.

  • innovations in data depth and breadth
  • need to aggregate information to inform intervention

Different players in value chains have different data needs

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Data Depth: Cumulative Understanding of disease

Data Depth: Cumulative number of oncology transactions

  • technology innovators rely on LEGACY businesses (those that already have technology) and these LEGACY businesses either have data breath or data depth BUT NOT BOTH; (IS THIS WHERE THE GREATEST VALUE CAN BE INNOVATED?)
  • NEED to provide ACTIONABLE as well as PHENOTYPIC/GENOTYPIC DATA
  • data depth more important in clinical setting as it drives solutions and cost effective interventions.  For example Foundation Medicine, who supplies genotypic/phenotypic data for patient samples supplies high data depth
  • technologies are moving to data support
  • evidence will need to be tied to umbrella value propositions
  • Informatic solutions will have to prove outcome benefit

 

 

 

 

 

How will Machine Learning be involved in the healthcare value chain?

  • increased emphasis on real time datasets – CONSTANT UPDATES NEED TO OCCUR. THIS IS NOT HAPPENING BUT VALUED BY MANY PLAYERS IN THIS SPACE
  • Interoperability of DATABASES Important!  Many Players in this space don’t understand the complexities integrating these datasets

Other Articles on this topic of healthcare informatics, value based oncology, and healthcare IT on this OPEN ACCESS JOURNAL include:

Centers for Medicare & Medicaid Services announced that the federal healthcare program will cover the costs of cancer gene tests that have been approved by the Food and Drug Administration

Broad Institute launches Merkin Institute for Transformative Technologies in Healthcare

HealthCare focused AI Startups from the 100 Companies Leading the Way in A.I. Globally

Paradoxical Findings in HealthCare Delivery and Outcomes: Economics in MEDICINE – Original Research by Anupam “Bapu” Jena, the Ruth L. Newhouse Associate Professor of Health Care Policy at HMS

Google & Digital Healthcare Technology

Can Blockchain Technology and Artificial Intelligence Cure What Ails Biomedical Research and Healthcare

The Future of Precision Cancer Medicine, Inaugural Symposium, MIT Center for Precision Cancer Medicine, December 13, 2018, 8AM-6PM, 50 Memorial Drive, Cambridge, MA

Live Conference Coverage @Medcity Converge 2018 Philadelphia: Oncology Value Based Care and Patient Management

2016 BioIT World: Track 5 – April 5 – 7, 2016 Bioinformatics Computational Resources and Tools to Turn Big Data into Smart Data

The Need for an Informatics Solution in Translational Medicine

 

 

 

 

Read Full Post »

« Newer Posts - Older Posts »